Abbott Laboratories (ETR:ABL)
Germany
· Delayed Price · Currency is EUR 121.30
+0.04 (0.03%)
Mar 31, 2025, 2:29 PM CET
Abbott Laboratories Revenue
In the year 2024, Abbott Laboratories had annual revenue of $41.95B USD with 4.59% growth. Abbott Laboratories had revenue of $10.97B in the quarter ending December 31, 2024, with 7.16% growth.
Revenue
$41.95B
Revenue Growth
+4.59%
P/S Ratio
n/a
Revenue / Employee
$367.98K
Employees
114,000
Market Cap
209.46B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 22.67B |
| Fresenius SE & Co. KGaA | 21.83B |
| Bayer Aktiengesellschaft | 46.61B |
| Sartorius Aktiengesellschaft | 3.38B |
| Fresenius Medical Care AG | 19.34B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
Abbott Laboratories News
- 3 days ago - Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday - The Motley Fool
- 4 days ago - Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms - PRNewsWire
- 5 days ago - Abbott Hosts Conference Call for First-Quarter Earnings - PRNewsWire
- 5 days ago - Behind the Scenes of Abbott Laboratories's Latest Options Trends - Benzinga
- 7 days ago - Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease - PRNewsWire
- 9 days ago - 2025 Dividend Kings: Strong Run Continues - Seeking Alpha
- 10 days ago - What Does the Market Think About Abbott Laboratories? - Benzinga
- 14 days ago - Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees - Seeking Alpha